Stüben, B.-O.; Stuhlfelder, J.; Kemper, M.; Tachezy, M.; Ghadban, T.; Izbicki, J.R.; Bokemeyer, C.; Sinn, M.; Karstens, K.-F.; Reeh, M.
Completion of FLOT Therapy, Regardless of Tumor Regression, Significantly Improves Overall Survival in Patients with Esophageal Adenocarcinoma. Cancers 2022, 14, 1084.
https://doi.org/10.3390/cancers14041084
AMA Style
Stüben B-O, Stuhlfelder J, Kemper M, Tachezy M, Ghadban T, Izbicki JR, Bokemeyer C, Sinn M, Karstens K-F, Reeh M.
Completion of FLOT Therapy, Regardless of Tumor Regression, Significantly Improves Overall Survival in Patients with Esophageal Adenocarcinoma. Cancers. 2022; 14(4):1084.
https://doi.org/10.3390/cancers14041084
Chicago/Turabian Style
Stüben, Björn-Ole, Jakob Stuhlfelder, Marius Kemper, Michael Tachezy, Tarik Ghadban, Jakob Robert Izbicki, Carsten Bokemeyer, Marianne Sinn, Karl-Frederick Karstens, and Matthias Reeh.
2022. "Completion of FLOT Therapy, Regardless of Tumor Regression, Significantly Improves Overall Survival in Patients with Esophageal Adenocarcinoma" Cancers 14, no. 4: 1084.
https://doi.org/10.3390/cancers14041084
APA Style
Stüben, B.-O., Stuhlfelder, J., Kemper, M., Tachezy, M., Ghadban, T., Izbicki, J. R., Bokemeyer, C., Sinn, M., Karstens, K.-F., & Reeh, M.
(2022). Completion of FLOT Therapy, Regardless of Tumor Regression, Significantly Improves Overall Survival in Patients with Esophageal Adenocarcinoma. Cancers, 14(4), 1084.
https://doi.org/10.3390/cancers14041084
